

# Hear Important Insights into Clinical Trials at the 13th Annual Clinical Trials in CNS Conference

*With an ever increasing average life expectancy, neurodegenerative diseases are becoming more prevalent in society.*

LONDON, SELECT STATE/PROVINCE, UNITED KINGDOM, July 4, 2014 /EINPresswire.com/ -- SMi is delighted to announce its 13th annual [Clinical Trials in CNS Conference](#). With an ever increasing average life expectancy, neurodegenerative diseases are becoming more prevalent in society. With this comes the need for new and improved therapies for treating neurodegenerative conditions. From Alzheimer's to Parkinson's disease, the target and mechanism by which a disease manifests itself presents unique challenges in how to approach such treatments not to mention ethical and legal issues behind treatment and trial design.



This conference will give delegates the opportunity to gain additional insights into the best practices in clinical trials, as well as address the challenges in CNS research and by looking at the latest pre-clinical and clinical studies.

This is an opportunity not to be missed, as we delve into the complex and exciting world of Central Nervous System discovery, allowing delegates to learn, explore and debate the key areas of CNS, its preclinical discovery and its clinical trials.

#### Reasons to Attend:

- Examine the multi-stakeholder approach to self-management and multidisciplinary care in patients with MS
- Discuss the past, present and future of CNS medicines research
- Analyse novel biomarkers for the brain
- Understand the recent failures in CNS development and how translation did not work
- Review the collaboration between industry and academic partnering

#### Key Speakers:

Tine Bryan Stensbøl, Divisional Director Discovery Pharmacology Research, Lundbeck

Alan Palmer, Co-Founder and Director, MS Therapeutics  
Veronique Bragulat, Clinical Imaging Manager, GSK  
Sophie Dix, Senior Research Scientist, Neurodegenerative Disease Drug Hunting Team, Eli Lilly  
David Willé, Applied Statistician, GSK  
Peter Joseph Jongen, Founding Director, MS4 Research Institute  
Ernst-Wilhelm Radue, CEO, MIAC AG  
Edwin Johnson, Director, Stockholm Brain Institute  
Shahid Zaman, Affiliated Lecturer, University of Cambridge

For more information please visit <http://www.smi-online.co.uk/2014clinicaltrials19.asp>

If you would like to attend this conference as a delegate please contact Filipa Ribeiro on +44 (0) 207 827 6020 or e-mail [fribeiro@smi-online.co.uk](mailto:fribeiro@smi-online.co.uk)

If you are interested in sponsoring this event contact Alia Malick on +44(0)20 7827 6168 or email [amalick@smi-online.co.uk](mailto:amalick@smi-online.co.uk)

If you would like to become a media partner contact Sarah Watson on +44 (0)20 7827 6134 or email [swatson@smi-online.co.uk](mailto:swatson@smi-online.co.uk)

Sarah Watson  
[email us here](#)  
SMi Group Ltd  
+44 (0) 207 827 6134

---

This press release can be viewed online at: <https://www.einpresswire.com/article/212336360>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.